Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of December 2020, specifically reporting a transaction notification dated December 30, 2020. The document serves as a disclosure of a transaction involving a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It is strictly a transaction notification regarding share ownership.
Material Changes
The filing details a single transaction involving the purchase of GSK Ordinary Shares:
- Transaction Type: Purchase of Ordinary Shares (25 pence each).
- Instrument: Ordinary Shares (ISIN: GB0009252882).
- Volume: 36,600 shares.
- Price: £13.7554 per share.
- Date: December 30, 2020.
- Location: London Stock Exchange (XLON).
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory disclosure of the specific share purchase transaction.
Transaction Parties
- PDMR/PCA: Mr. V Banga (Senior Independent Non-Executive Director).
- Issuer: GlaxoSmithKline plc (LEI: 5493000HZTVUYLO1D793).
Key Facts for Investor Verification
- Verify the total number of shares held by Mr. V Banga following this purchase to assess total exposure.
- Confirm the transaction price of £13.7554 against the market closing price on December 30, 2020.
- Note that this filing does not reflect the company's overall financial performance for the period.